OPEN END TURBO LONG - ORION B | Delayed Börse Stuttgart 11:34:08 2024-05-17 am EDT | ||
| 0.71 EUR | +1.43% |
|
| 1 month | +233.33% | ||
| 3 months | -24.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.71 | +1.43% |
| 24-05-16 | 0.7 | -5.41% |
| 24-05-15 | 0.74 | +5.71% |
| 24-05-14 | 0.7 | +7.69% |
| 24-05-13 | 0.65 | -8.45% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 11:34 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | ME4SCX |
| ISIN | DE000ME4SCX1 |
| Date issued | 2023-12-06 |
| Strike | 30.55 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.5 € |
|---|---|
| Lowest since issue | 0.182 € |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.69
EUR
Average target price
39
EUR
Spread / Average Target
+3.48%
- Stock Market
- Certificates
- Certificat
